Pathogenesis of Chronic Fatigue Syndrome, a Multisystem Hypothesis

Journal of Chronic Fatigue Syndrome

Volumn 11, Issue 3, 2003, Pages 51-68

  Shor, Samuel ^a  

^a GW University Health Care Sciences   (United States)

Author keywords

CFS; Chronic fatigue syndrome; Fatigue

Indexed keywords

BLOOD PRESSURE REGULATION; CARDIOVASCULAR FUNCTION; CHRONIC FATIGUE SYNDROME; COGNITIVE DEFECT; DIAGNOSTIC TEST; DISEASE DURATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENVIRONMENTAL EXPOSURE; GENETIC PREDISPOSITION; HEART RATE; HORMONE DEFICIENCY; HUMAN; IMMUNE SYSTEM; INFECTION; NEUROENDOCRINE SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATHOPHYSIOLOGY; RELAPSE; REVIEW; SLEEP DISORDER;

EID: 0142200981     PISSN: 10573321     EISSN: None     Source Type: Journal    
DOI: 10.1300/J092v11n03_05     Document Type: Review

References (77)

1. Holmes GP, Kaplan JE, Gantz NM, Komaroff AL, Schonberger LB, Strauss SE, et al. Chronic Fatigue Syndrome: A working case definition. Ann Intern Med 1988; 108:387-389.
2. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A, et al. The Chronic Fatigue Syndrome: A comprehensive approach to its definition and study. Ann Intern Med 1994; 121:953-960.
3. Bates DW, Schmitt W, Buchwald D, Ware NC, Lee J, Thoyer E, et al. Prevalence of fatigue and chronic fatigue syndrome in a primary care practice. Arch Intern Med 1993; 153:2759-2765.
4. Buchwald D, Umali P, Umali J, Kith P, Pearlman T, Komaroff AL. Chronic fatigue and the chronic fatigue syndrome: Prevalence in a Pacific Northwest health care system. Ann Intern Med 1995; 123:81-88.
5. Levine P. What we know about Chronic Fatigue Syndrome and its relevance to the practicing physician. Am J Med 1998; 105:100S-103S.
6. Komaroff AL, Buchwald DS. Chronic Fatigue Syndrome: An update. Annu Rev Med 1998; 49:1-13.
7. Klimas NG, Salvato FR, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol 1990; 28:1403-1410.
8. Lloyd AR, Wakefield D, Boughton CR, Dwyer JK. Immunologic abnormalities in the chronic fatigue syndrome. Med J Aust 1989; 151:122-124.
9. Caligiuri M, Murry C, Buchwald D, et al. Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. J Immunol 1987; 139:3306-3313.
10. Eby N, Grufferman S, Huang M, et al. Natural killer cell activity in the chronic fatigue-immune dysfunction syndrome. In: Ades EW, Lopez C, editors Natural Killer Cells and Host Defens Basel: Karger, 1988:141-145.
11. Maher K. Flow cytometric measurements of perforin and natural killer cell activity poster communication. American Association for Chronic Fatigue Syndrome Fifth International Conference, Seattle, January 2001.
12. Chao CC, Janoff EN, Hu SX, et al. Altered cytokine release in peripheral blood mononuclear cell cultures from patients with the chronic fatigue syndrome. Cytokine 1991; 3:292-296.
13. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998; 128:127-137.
14. Hurwitz BE, Brownely KA, Fletcher MA, Klimas NG. Chronic fatigue syndrome: Evidence supporting the hypothesis of a behaviorally-activated neuromodulator of fatigue. JCFS 2000; 6:45-63.
15. Aoki T, Miyakoshi H, Usuda Y, Herberman RB. Low NK syndrome and its relationship to chronic fatigue syndrome. Clin Immunol Immunopathol 1993; 69:253-265.
16. MacDonald KL, Osterholm MT, LeDell KH, White KE, Schenck CH, Chao CC. A case-control study to assess possible triggers and cofactors in chronic fatigue syndrome. Am J Med 1996; 100:549-553.
17. Buchwald D, Herrell R, Ashton S, et al. A twin study of Chronic Fatigue. Psychosomatic Medicine 2001; 63:936-943.
18. Sigal LH. Summary of the first 100 patients seen at a Lyme disease referral center. Am J Med 1990; 88:577-581.
19. Salit IE. Precipitating factors for the chronic fatigue syndrome. J Psychiat 1997; 31:59-65.
20. Scott LV, Medbak S, Dinan TG. Blunted adrenocorticotropin and cortisol responses to corticotropin-releasing hormone stimulation in chronic fatigue syndrome. Acta Psychiatr Scand 1998; 97:450-457.
21. De Becker P, De Meirler K, Joos E, et al. Attenuated DHEA response to i.v. ACTH injection in patients with chronic fatigue syndrome. Poster communication. First World Congress on Chronic Fatigue Syndrome and Related Disorders, Brussels, 1995.
22. Kellner M, Wiedmann K, Holsboer F. Atrial natriuretic factor inhibits the CRH-stimulated secretion of ACTH and cortisol in man. Life Sci 1992; 50:1835-1842.
23. Demitrack MA. Neuroendocrine correlates of chronic fatigue syndrome: A brief review. J Psychiatr Res 1997; 31:69-82.
24. Sutton RE, Koob GF, LeMoal M, Rivier J, Vale W. Corticotropin-releasing factor produces behavioral activation in rats. Nature 1982; 297:331-333.
25. Scott LV, Dinan TG. Urinary free cortisol excretion in chronic fatigue syndrome, major depression and in healthy volunteers. J Affective Dis 1998; 47:49-54.
26. Joyce E, Blumenthal S, Wessely S. Memory, attention, and executive function in chronic fatigue syndrome. J Neurol Neurosurg Psychiat 1996; 60:495-503.
27. Freeman R, Komaroff A. Does the chronic fatigue syndrome involve the autonomic nervous system? Am J Med 1997; 102:357-364.
28. Schondorf R, Freeman R. The importance of orthostatic intolerance in the chronic fatigue syndrome. Am J Med Sci 1999; 317:117-123.
29. Manyari DE, Rose S, Tyberg JV, Sheldon RS. Abnormal reflex venous function in patients with neruomediated syncope. J Am Coll Cardiol 1996; 27:1730-1735.
30. Leese G, Chattington P, Fraser W, et al. Short-term night-shift work mimics the pituitary-adrenal dysfunction in chronic fatigue syndrome. J Clin Endocrinol Metab 1996; 81:1867-1870.
31. Holsboer F, Von Bardeleben U, Gerken A, Stall GK, Muller OA. Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression. N Engl J Med 1984; 311:1127.
32. Johnson SK, DeLuca J, Fiedler N, Natelson BH. Cognitive functioning of patients with chronic fatigue syndrome. Clin Infect Dis 1994; 18:S84-S85.
33. Marcel B, Komaroff AL, Fagioli LR, Kornish RJ, Albert MS. Cognitive deficits in patients with chronic fatigue syndrome. Biol Psychiatry 1996; 40:535-541.
34. Micels V, Cluydts R, Fischler B, Hoffmann G, Le Bon O, De Meirleir K. Cognitive functioning in patients with chronic fatigue syndrome. J Clin Exp Neuropsychol 1996; 18:666-677.
35. DeLuca J, Johnson SK, Beldowicz D, Natelson BH. Neuropsychological impairments in chronic fatigue syndrome, multiple sclerosis and depression. J Neurol Neurosurg Psychiat 1995; 58:38-43.
36. Lange G, Wang S, DeLuca J, Natelson B. Neuroimaging in chronic fatigue syndrome. Am J Med 1998; 105:50S-53S.
37. Glaser R, Kiecolt-Glaser JK. Stress-associated immune modulation: Relevance to viral infections and chronic fatigue syndrome. Am J Med 1998; 105:35S-42S.
38. Peterson DL. Chair Section Role of the Brain in the Pathogenesis of Medically Unexplained Symptoms 2003 6th International AACFS Conference on Chronic Fatigue Syndrome, Fibromyalgia and related illnesses.
39. Evangard B, Schacterle RS, Komaroff AL. Chronic fatigue syndrome: New insights and old ignorance. J Intern Med 1999; 246:455-469.
40. Steere AC, Taylor E, McHugh GL, Logigian EL. The overdiagnosis of Lyme disease. JAMA 1993; 269:1812-1816.
41. Coyle PK, Drupp LB, Doscher C, Amin K. Borrelia burgdorferi reactivity in patients with severe persistent fatigue who are from a region in which Lyme disease is endemic. Clin Infect Dis 1994; 18:S24-S27.
42. Marmion BP, Shannon M, Maddocks I, Storm P, Pentitla I. Protracted debility and fatigue after acute Q fever. Lancet 1996; 347:977-978.
43. Buchwald D, Cheney PR, Peterson D, et al. Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. Ann Intern Med 1985; 102:7-16.
44. Yalcin S, Kuratsune H, Yamaguchi K, Kitani T, Uamanishi K. Prevalence of human herpesvirus 6 variants A and B in patients with chronic fatigue syndrome. Microbiol Immunol 1994; 38:587-590.
45. Patnaik M, Komaroff AL, Conley E, Ojo-Amaize EA, Peter JB. Prevalence of IgM antibodies to human herpesvirus 6 early antigen (p41/38) in patients with chronic fatigue syndrome. J Infect Dis 1995; 172:1364-1367.
46. Zorezenon M, Rukh G, Botta GA, Colle R, Barsanti LA, Ceccherini-Nelli L. Active HHV-6 infection in chronic fatigue syndrome patients from Italy: New data. J Infect Dis 1996; 2:3-12.
47. Nakaya T, Takahashi H, Nakamura Y, et al. Demonstration of Borna disease virus RNA in peripheral blood mononuclear cells derived from Japanese patients with chronic fatigue syndrome. FEBS Lett 1996; 378:145-149.
48. Kitani T, Kuratsune H, Fuke I, et al. Possible correlation between Borna disease virus infection and Japanese patients with chronic fatigue syndrome. Microbiol Immunol 1996; 40:459-462.
49. Evengard B, Briese T, Lindh G, Lee S, Lipkin WI. No evidence of Borna disease virus in Swedish patients with chronic fatigue syndrome. J Neurovirology 1999; 5:495-499.
50. Pall ML. Elevated, sustained peroxynitrite levels as the cause of chronic fatigue syndrome. Med Hypoth 2000; 54:115-125.
51. Chao CC, Lokensgard JR, Sheng WS, Hu S, Peterson PK. IL-induced iNOS expression in human astrocytes via NK-αβ. Neuroreport 1997; 8:3163-3166.
52. Pahan K, Sheikh FG, Namboodiri AM, Singh L. N-acetyl cysteine inhibits induction of NO production by endotoxin or cytokine stimulated rat peritoneal macrophages, C6 glial cells and astrocytes. FreeRadic Biol Med 1998; 24:39-48.
53. Holzmann A. Nitric oxide and sepsis. Respir Care Clin N Am 1997; 3:537-550.
54. Beckman JS, Crow JP. Pathological implications of nitric oxide, superoxide and peroxynitite formation. Biochem Soc Trans 1993; 21:330-334.
55. Radi R, Rodriguez M, Castro L, Telleri R. Inhibition of mitochondrial electron transport by peroxynitrite. Arch Biochem Biophys 1994; 308:89-95.
56. Schedlowski M, Jacobs R, Stratmann G, et al. Changes in natural killer cells during acute psychological stress. J Clin Immunol 1993; 13:119-126.
57. Siber WJ, Rodin J, Larson L, et al. Modulation of human natural killer cell activity by exposure to uncontrollable stress. Brain Behav Immun 1992; 6:141-156.
58. Stevens A, Kloter I, Roggendorf W. Inflammatory infiltrates and natural killer cell presence in human brain tumors. Cancer 1988; 61:738-743.
59. Whiteside T, Friberg, D. Natural killer cells and natural killer cell activity in chronic fatigue syndrome. Am J Med 1998; 105:27S-34S.
60. Ottaway CA, Husband AJ. Central nervous system influences on lymphocyte migration. Brain Behav Immun 1992; 6:97-116.
61. Breviario F, Proserpio P, Bertocchi F, Lampugnani MG, Mantovani A, Dejana E. Interleukin-1 stimulates prostacyclin production by cultured human endothelial cells by increasing arachidonic acid mobilization and conversion. Arteriosclerosis 1990; 10:129-134.
62. Mantovani A, Bussolino F, Dejana E. Cytokine regulation of endothelial cell function. FASEB J 1992; 6:2591-2599.
63. Dejana E, Breviario F, Erroi A, et al. Modulation of endothelial cell functions by different molecular species of interleukin 1. Blood 1987; 69:695-699.
64. Gulick T, Ching MK, Pieper SJ. Interleukin-I and tumor necrosis factor inhibits cardiac myocyte beta-adrenergic responses. Proc Natl Acad Sci USA 1989; 86:6753-6757.
65. Krupp LB, Jandorf L, Coyle PK, Mendelson WB. Sleep disturbance in chronic fatigue syndrome. J Psychosom Res 1993; 37:325-331.
66. Moldofsky H. Sleep and fibrositis syndrome. Rheumatic disease of NA (Edited by Bennet RM, Goldenberg DL) 1989; 15:92-103.
67. Mullington JM, Hinze-Selch D, Pollmacher T. Mediators of inflammation and their interaction with sleep. Relevance for chronic fatigue syndrome and related conditions. Annals NY Acad Sc 2001; 933:201-210.
68. Borish L, Schmaling K, Di Clementi JD, et al. Chronic fatigue syndrome: Identification of distinct subgroups on the basis of allergy and psychological variables. J Allergy Clin Immunol 1998; 102:222-230.
69. Rowe PC, Clakins H. Neurally mediated hypotension and chronic fatigue syndrome. Am J Med 1998; 105:15S-21S.
70. Demitrak MA, Dale JK, Strauss SE, et al. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab 1991; 73:1223-1234.
71. Ehlers CL, Kupfer DJ. Hypothalamic peptide modulation of sleep EEG in depression: A further application of the S-process hypothesis. Biol Psychiatry 1987; 22:513-517.
72. Steiger A, Guldner J, Knisatschek H, et al. Effects of growth-hormone releasing hormone and somatostatin on sleep EEG and nocturnal hormone secretion in male controls. Neuroendocrinology 1992; 56:566-573.
73. Marshall PS, Forstot M, Callies A, Peterson P, Schenck CH. Cognitive slowing and working memory difficulties in chronic fatigue. Psychosomatic Medicine 1997; 59:58-66.
74. DeLuca J, Johnson SK, Ellis SP, Natelson BH. Cognitive functioning is impaired in patients with chronic fatigue syndrome devoid of psychiatric disease. J Neurol Neurosurg Psychiatry 1997; 62:151-155.
75. Suhadolnik RJ, Peterson DL, Reichenbach NL, et al. Chronic fatigue syndrome is distinct from depressed and healthy controls: Biochemical and clinical differences. Presentation at the biannual 2003AACFS International Conference on CFS.
76. Costa DC, Tannock C, Brostoff J. Brainstem perfusion is impaired in chronic fatigue syndrome. Q J Med 1995; 88:767-773.
77. Tirelli U, Chierchetti F, Tavio M, et al. Brain Positron Emission Tomography (PET) in chronic fatigue syndrome: Preliminary data. Am J Med 1998; 105:54S.